Thomas W. LeBlanc, MD, MA, discusses key clinical pearls for community oncologists in the treatment of anemia in patients ...

Given all the treatment strategies and key updates discussed today, what are your overall thoughts on luspatercept in the LR-MDS treatment landscape? What clinical pearls can you leave for community ...

The first patient has been dosed in a phase 1 dose-finding clinical trial evaluating iadademstat with Vidaza in patients with ...

Salarius Pharmaceuticals, Inc. (NASDAQ:SLRX) has announced the resumption of patient enrollment in a Phase 1/2 clinical trial evaluating seclidemstat combined with azacitidine for myelodysplastic ...

Here is a select list of cancer therapies approved by the FDA throughout the month of January, featuring patient populations ...

Request an Appointment Fred Hutch: A Leader in MDS Treatment Fred Hutch is recognized as a Center of Excellence by the Myelodysplastic Syndromes Foundation for the diagnosis and treatment of MDS. Our ...

Researchers of one abstract retrospectively analyzed data from over 2000 patients with MDS—either high risk or low risk—and found that IDH1-targeted treatment may yield improved outcomes for ...

Mikkael A. Sekeres, MD, Sylvester Comprehensive Cancer Center, discusses the potential benefits of treosulfan, a newly ...

Treosulfan (Grafapex) was approved in Canada in June 2021 for the same use and is marketed under the brand name Trecondyv.

A RECENT study has shed light on the particularly poor prognosis faced by patients who develop acute myeloid leukaemia (AML) after receiving treatment for myelodysplastic syndrome (MDS) or related ...

Treatment with exenatide, a GLP-1 receptor agonist, was comparable to placebo in slowing the rate of Parkinson’s disease ...